Does China Accept Foreign Clinical Trial Data for NMPA Drug Registration Applications?

A comprehensive analysis of NMPA’s acceptance of foreign clinical data, bridging study requirements, and strategic pathways for foreign biotech companies.

Introduction

One of the most significant developments in China’s pharmaceutical regulatory landscape has been the progressive acceptance of foreign clinical trial data for NMPA drug registration applications. Since China became a full member of the International Council for Harmonisation (ICH) in 2017, the NMPA and CDE have implemented policies that allow foreign companies to leverage global clinical trial data for Chinese regulatory submissions, potentially eliminating the need for separate, costly, and time-consuming China-only clinical trials. This article provides a comprehensive examination of when and how foreign clinical trial data is accepted by the NMPA, the bridging study requirements under ICH E5 and E17, ethnic sensitivity analysis expectations, and strategic considerations for foreign biotech companies seeking to optimize their China registration strategy in 2025–2026.

The Regulatory Evolution: From Full Duplication to Data Acceptance

China’s approach to foreign clinical data has evolved through three distinct phases:

• Pre-2017 (Full Duplication Era): The NMPA required foreign companies to conduct complete clinical trial programs in China, effectively duplicating the global clinical development effort. This added 3–7 years to the China registration timeline and made China one of the last major markets for new drug launches.
• 2017–2020 (Transition Period): Following ICH membership, the NMPA issued Announcement No. 7 (2017) and subsequently the 2018 guideline on acceptance of foreign clinical data. During this transition, the NMPA began accepting foreign clinical data but required China-specific bridging studies for most new drug applications.
• 2020–Present (ICH Alignment Era): The 2020 Measures for Drug Registration fully integrated ICH E5 (Ethnic Factors) and ICH E17 (Multi-Regional Clinical Trials) principles. Under current regulations, foreign clinical trial data can be accepted for NMPA registration subject to ethnic sensitivity analysis and, where needed, limited bridging studies. For products that include Chinese patients in global MRCTs, the acceptance path is even more streamlined.

ICH E5: The Framework for Accepting Foreign Clinical Data

The ICH E5 guideline on “Ethnic Factors in the Acceptability of Foreign Clinical Data” provides the foundational framework for NMPA’s acceptance of foreign clinical data. Under ICH E5, the key concepts are:

• Ethnic factors: The CDE considers both intrinsic ethnic factors (genetic polymorphisms, metabolic differences, body weight, organ function) and extrinsic ethnic factors (diet, environmental exposures, medical practices, diagnostic criteria, concomitant medications) that may affect a drug’s safety, efficacy, or dosing requirements in Chinese populations.
• Bridging study: A bridging study is designed to generate additional data on the drug’s pharmacokinetics, pharmacodynamics, safety, or efficacy in the new region to bridge the foreign clinical data. A bridging study can be as simple as a pharmacokinetic comparison study or as comprehensive as a full Phase III trial including Chinese patients.
• Complete clinical data package (CCDP): The foreign company must submit the complete clinical data package from the original development program, including all Phase I–III study reports, integrated safety and efficacy summaries, and the clinical study report (CSR) for each completed trial.
• Bridging data package (BDP): Based on the ethnic sensitivity of the drug, the CDE determines whether a bridging study is needed and, if so, what type and size of bridging study is appropriate. The BDP is submitted alongside the CCDP as part of the NDA.

ICH E17: Multi-Regional Clinical Trials (MRCTs)

ICH E17 on MRCT planning and design provides an even more efficient pathway for foreign companies to generate China-acceptable clinical data. Under the MRCT approach:

• China sites included in global trials: Foreign companies can include Chinese investigational sites in their global Phase II and III trials from the outset. This approach generates data on Chinese patients within the same protocol, using the same procedures, endpoints, and analysis methods as the global trial.
• Consistency assessment: The CDE requires a statistical assessment of consistency between Chinese patient results and overall trial results. The ICH E17 guideline recommends at least 15–20% of the global sample size from Chinese sites, though the exact percentage depends on the drug’s inherent ethnic sensitivity and the targeted effect size.
• Regulatory acceptance: Drugs developed through MRCTs with adequate Chinese patient participation may qualify for NMPA registration based on the MRCT data alone, without requiring a separate China-specific bridging study.
• Early CDE consultation: The CDE strongly encourages foreign companies to consult on MRCT designs before trial initiation to ensure the Chinese cohort size and analysis plan are acceptable.

When Is a China-Specific Bridging Study Still Required?

Despite significant progress in data acceptance, China-specific clinical data may still be required in the following situations:

• Highly ethnically sensitive drugs: Drugs with narrow therapeutic windows, extensive hepatic or renal metabolism, or known ethnic differences in PK/PD profiles may require a Phase I PK bridging study in Chinese subjects even after MRCTs.
• Biologics with high immunogenicity risk: Monoclonal antibodies, fusion proteins, and other biologics may show different immunogenicity profiles in Chinese populations due to genetic differences in HLA types and immune response genes. The CDE may require an immunogenicity substudy or extended safety monitoring in Chinese patients.
• Traditional Chinese medicines or natural products: Products with botanical or TCM components generally require China-specific safety and efficacy data.
• Diseases with different epidemiology in China: For conditions where disease presentation, progression, or treatment patterns differ significantly between China and Western countries (e.g., hepatitis B, gastric cancer, nasopharyngeal carcinoma), the CDE may require China-specific efficacy data.
• Drugs for indications with different standard of care in China: If the standard of care treatment for a condition differs meaningfully between China and the foreign trial locations, a China-specific comparison study may be necessary.

The Ethnic Sensitivity Analysis: Key Documentation

Regardless of whether a bridging study is required, all NMPA applications based on foreign clinical data must include a comprehensive ethnic sensitivity analysis (ESA). The ESA document should include:

• Drug characteristics assessment: Analysis of the drug’s pharmacokinetic properties, metabolic pathways, pharmacodynamic effects, and known ethnic sensitivity factors from the preclinical and clinical development program.
• Comparative PK/PD analysis: Available data comparing the drug’s pharmacokinetics and pharmacodynamics in Chinese vs. non-Chinese populations. This may include subgroup analyses from global trials, population PK modeling, or dedicated PK bridging studies.
• Clinical safety and efficacy by region: Subgroup analyses of safety and efficacy outcomes by geographic region or racial/ethnic group from the global clinical program.
• Extrinsic factor assessment: Analysis of potential differences in medical practice, diagnostic criteria, concomitant medications, diet, and environmental exposures between China and the foreign trial sites.
• Bridging strategy recommendation: A clear proposal on whether a bridging study is needed and, if so, what type (PK bridging, safety bridging, full efficacy bridging) and the recommended sample size.

Acceptance of Clinical Data from Specific Regions

The NMPA and CDE evaluate foreign clinical data based on the quality and regulatory standards of the source country, with the following generally accepted hierarchy:

• US FDA and EU EMA data: Clinical data generated under US FDA or EU EMA IND applications and GCP-compliant trials is generally given the highest level of acceptance. The NMPA has mutual recognition arrangements or informal acceptance practices for data from these jurisdictions.
• ICH-member country data: Clinical data from other ICH member countries (Japan, South Korea, Canada, Switzerland, Australia, UK, etc.) is also well accepted, though the CDE may request additional ethnic sensitivity analysis for drugs developed primarily in populations genetically distinct from Chinese (e.g., predominantly Caucasian populations).
• Non-ICH country data: Clinical data from countries with less established regulatory systems is subject to more scrutiny and may require additional quality verification or in-country bridging studies.

Practical Pathway Selection: Which Approach Is Right for Your Drug?

Foreign biotech companies should choose among three main pathways for generating clinical data acceptable to the NMPA:

• Pathway A: Full reliance on foreign data with limited bridging (low ethnic sensitivity drugs): For drugs with low ethnic sensitivity — extensive safety margins, simple PK profiles, well-understood mechanisms of action — the NMPA may accept the global clinical package with only a small PK bridging study (20–40 Chinese healthy volunteers) plus subset analyses from global Phase III data. Total incremental timeline: 3–6 months. Best for: well-characterized chemical drugs, generic drugs, biosimilars with extensive global safety data.
• Pathway B: MRCT with Chinese sites (moderate ethnic sensitivity drugs): For most innovative drugs, including Chinese sites in global Phase II and III MRCTs is the most efficient approach. The MRCT data package, combined with consistency analysis, can support NMPA registration without separate China-only studies. Total incremental timeline: 6–12 months (for site initiation and enrollment). Best for: innovative chemical drugs, monoclonal antibodies, targeted therapies.
• Pathway C: China-first or China-parallel full clinical program (high ethnic sensitivity drugs): For drugs expected to have significant ethnic sensitivity, a dedicated China clinical program (Phase I–III) may be required. Running the China program in parallel with global development can minimize timeline impact. Total incremental timeline: 12–24 months for parallel development. Best for: gene therapies, cell therapies, highly immunogenic biologics, drugs for China-prevalent diseases.

Common Pitfalls and How to Avoid Them

Foreign biotech companies frequently encounter the following issues when seeking NMPA acceptance of foreign clinical data:

• Inadequate ethnic sensitivity analysis: Submitting a generic ESA without drug-specific data or analysis. Solution: Invest in a thorough, data-driven ESA prepared by experienced China regulatory consultants.
• Insufficient Chinese patient data in MRCTs: Including too few Chinese patients for meaningful consistency analysis. Solution: Ensure the Chinese cohort size is statistically justified and preferably exceeds 15% of the total MRCT sample size.
• Inconsistent data standards: Differences in data collection methods, endpoint definitions, or statistical analysis plans between the global program and CDE expectations. Solution: Align trial designs with CDE expectations during the pre-IND consultation phase.
• Human genetic resources compliance failure: Exporting or analyzing Chinese patient biospecimens without HGR approval. Solution: Obtain HGR approval before specimen collection and use China-based testing laboratories where possible.
• Data localization gaps: Global clinical databases not accessible from China. Solution: Establish China-based clinical data repositories and ensure compliance with PIPL for cross-border data transfers.

Conclusion

Yes, China accepts foreign clinical trial data for NMPA drug registration applications. Since joining the ICH in 2017 and implementing ICH E5 and E17 guidelines, the NMPA and CDE have created a well-defined pathway for accepting global clinical data subject to ethnic sensitivity analysis and appropriate bridging studies. For foreign biotech companies, the optimal approach depends on the drug’s ethnic sensitivity profile, therapeutic area, development stage, and strategic priorities. Including Chinese sites in global MRCTs has emerged as the most efficient pathway for most innovative drugs, while drugs with low ethnic sensitivity may qualify for NMPA approval with minimal additional China-specific data. By understanding these pathways and engaging the CDE early in the development process, foreign biotech companies can significantly reduce the time and cost of bringing their drugs to the Chinese market.

This article is for informational purposes only and does not constitute legal or regulatory advice. Regulations regarding acceptance of foreign clinical data are subject to change. Foreign companies should consult qualified regulatory affairs professionals for guidance on their specific drug development programs and NMPA registration strategies.